Novartis will be presenting work done in collaboration with SciCross at the 15th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals in Lisbon later this month. The poster to be presented can be found here. This work describes how drug/pathogen analogy can be considered in the immunogenicity risk assessment of biologics.
New paper published in Lancet Rheumatology on immune cell signatures in JSLE patients, discovered by machine learning techniques AND extensive laboratory work AND clinical knowledge. Really happy to have the privilege to collaborate with this amazing group of people!
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30168-5/fulltext
#Machinelearning #AI #UCL #JSLE
SciCross partners with scientists from Uppsala University, KTH and SciLifeLab in developing Covid-19 treatments in immune suppressed individuals. The project is called “An adaptable therapeutic technology platform to treat SARS-CoV infections in immune suppressed individuals” and has received funding from SciLifeLab and Knut and Alice Wallenberg Foundation (https://kaw.wallenberg.org/). SciCross focus will be on identifying parts in the SARS-CoV-2 genome that can elicit an immune response towards the virus. More details about the project will follow soon.
In a recent paper written with colleagues from the ABIRISK consortium we present a study of the genetic risk associated with inhibitor development in patients with severe hemophilia A. #ABIRISK #immunogenicity
https://www.ncbi.nlm.nih.gov/pubmed/31194850
A better understanding of the blood-brain barrier (BBB) is key for developing treatments for disease like MS and Alzheimer’s. In a collaboration with AstraZeneca, KTH, Karolinska Institute and University of Skövde we recently published an article studying the use of human stem cells to generate in vitro models of the BBB. More specifically, we studied the barrier properties and transcriptome of iPSC-derived models. Check out the full article published in Stem Cells (pubmed).
In a recent paper, published in Journal of Clinical Investigation Insight, we describe a number of factors that influence the risk of immunogenicity responses (anti drug antibodies, ADA) in Multiple Sclerosis patients treated with Interferon beta (IFN-β). We found that NOTCH2 expression on CD14+ cells and increased frequency of proinflammatory monocyte subsets can be used as baseline predictors of neutralizing ADA (nADA) in MS patients treated with IFN-β. Further investigation of NOTCH2 showed that nADA development was driven by a proinflammatory environment that triggered activation of the NOTCH2 signaling pathway prior to first IFN-β administration.
Check out the full paper.
In a collaboration with the University of Tübingen and Harvard Medical School we have published a paper on how to reduce immunogenicity and at the same time keep protein stability/function. The approach is based on multi-objective combinatorial optimisation and was tested on the C2 domain of Factor VIII. For the full paper, go to Population-specific design of de-immunized protein biotherapeutics.
On April 1 the 1st ABIRISK Drug Immunogenicity Conference was held in Innsbruck, Austria. There were many highly interesting talks at this meeting, ranging from regulatory perspective by Amy Rosenberg FDA to a mathematical framework for prediction of therapeutic drug immunogenicity by Pfizer. SciCross presented an overview of the ABIRISK database, work that is done in collaboration with the IMI eTRIKS consortia.
The ABIRISK yearly general assembly and workpackage-specific meetings were held in Innsbruck the days before the conference. Here SciCross presented a tool for integration and analysis of data generated in a range of assays focused immunogenicity assessment of biopharmaceuticals. Please feel free to contact us for further discussions on this topic.
SciCross is happy to announce a new collaboration focused on modelling the human blood-brain-barrier using innovative in vitro and stem cell approaches. The project is a collaboration between the University of Skövde, Biolamina, 3Dtro, AstraZeneca and SciCross.
SciCross has contributed to work that will be presented at the European Congress of Immunology 2015, held in Vienna. The titles are ‘Risk factors of anti-drug antibodies (ADA) occurrence in multiple sclerosis ‘ and ‘Antibodies against interferon beta and natalizumab in European multiple sclerosis patients’. This work has been conducted in the scope of the ABIRISK project.